Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Health ministry warns of increased nationwide dengue risk as cases rise

Malaysia saw a 56.2% increase in dengue cases as of Aug 15 compared with the same period last year, says the ministry.

Health ministry warns of increased nationwide dengue risk as cases rise

Malaysia's health ministry has issued a warning about a rising nationwide risk of dengue, with cases increasing by 56.2% compared to the same period in 2025. As of August 15, 2026, there were 58,079 reported dengue cases, with 55 fatalities reported due to dengue-related complications within the 32nd epidemiological week of 2026.

The ministry identified unattended water containers in residential areas, particularly where Aedes mosquitoes breed, as a contributing factor to the rising cases. Other factors include fluctuating weather conditions, which create a suitable environment for mosquito breeding. The ministry advised the public to spend at least 10 minutes weekly inspecting their homes to eliminate potential mosquito breeding sites and take personal protective measures against mosquito bites.

It emphasized the need for a collective effort to prevent and control dengue cases, as over 70% of mosquito breeding sites are still found in residential areas.

Written by urgent.news from Free Malaysia Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at freemalaysiatoday.com →

More in Health & Medicine

Celltrion Expands Japan Autoimmune Portfolio With Steqeyma IV Launch

Celltrion has launched the intravenous formulation of its ustekinumab biosimilar Steqeyma in Japan, expanding an autoimmune disease portfolio that already includes market-leading biosimilars Remsima…

  • Celltrion launches Steqeyma IV, an ustekinumab biosimilar, in Japan.
  • Leverages Japan's market and existing relationships to boost product lineup.
  • Offers IV and subcutaneous formulations for flexibility in treatment.

More from Friday 21 August →